As Cushing's disease continues to rise worldwide and contributes significantly to serious comorbidities such as diabetes, cardiovascular disorders, and certain cancers, the need for safer and more effective therapeutic options is becoming increasingly urgent. According to DelveInsight, the Cushing's disease pipeline currently includes 4+ pharmaceutical and biotechnology companies actively advanc..